MedPath

MITSUBISHI TANABE PHARMA CORPORATION

πŸ‡―πŸ‡΅Japan
Ownership
-
Employees
-
Market Cap
-
Website

MT-3534 Clinical Pharmacology Study in Healthy Adult Male Volunteers

Phase 1
Not yet recruiting
Conditions
Healthy Adult Male Volunteers
Interventions
Biological: Placebo
Biological: MT-3534
First Posted Date
2024-07-01
Last Posted Date
2024-07-01
Lead Sponsor
Mitsubishi Tanabe Pharma Corporation
Target Recruit Count
56
Registration Number
NCT06482346
Locations
πŸ‡―πŸ‡΅

Clinical Research Hospital Tokyo, Shinjuku-ku, Tokyo, Japan

An Exploratory Study of MT-2990 in Patients With AAV

Phase 1
Recruiting
Conditions
Antineutrophil Cytoplasmic Antibody (ANCA) -Associated Vasculitis (AAV)
Interventions
Drug: MT-2990
First Posted Date
2024-01-09
Last Posted Date
2024-08-26
Lead Sponsor
Mitsubishi Tanabe Pharma Corporation
Target Recruit Count
10
Registration Number
NCT06196905
Locations
πŸ‡―πŸ‡΅

Kagawa University Hospital, Kita-gun, Kagawa, Japan

πŸ‡―πŸ‡΅

Saitama Medical Center, Kawagoe, Saitama, Japan

πŸ‡―πŸ‡΅

Hiroshima University Hospital, Hiroshima-shi, Hiroshima, Japan

and more 5 locations

A Study of MT-2111 in Patients With Relapsed/Refractory DLBCL

Phase 1
Recruiting
Conditions
Diffuse Large B-Cell Lymphoma
Interventions
Drug: MT-2111
First Posted Date
2022-12-20
Last Posted Date
2024-10-07
Lead Sponsor
Mitsubishi Tanabe Pharma Corporation
Target Recruit Count
49
Registration Number
NCT05658562
Locations
πŸ‡―πŸ‡΅

Osaka Saiseikai Nakatsu Hospital, Osaka-shi, Osaka, Japan

πŸ‡―πŸ‡΅

Nagoya Medical Center, Nagoya-shi, Aichi, Japan

πŸ‡―πŸ‡΅

Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital, Nagoya-shi, Aichi, Japan

and more 16 locations

Extension Study Following the Studies MT-1186-A03 or A04 to Evaluate the Safety of Oral Edaravone in Subjects With ALS

Phase 3
Completed
Conditions
ALS
Interventions
Drug: MT-1186
First Posted Date
2022-10-05
Last Posted Date
2023-10-27
Lead Sponsor
Mitsubishi Tanabe Pharma Corporation
Target Recruit Count
15
Registration Number
NCT05568615
Locations
πŸ‡―πŸ‡΅

National Hospital Organization Kumamoto Saishun Medical Center, Koshi, Kumamoto, Japan

πŸ‡―πŸ‡΅

National Epilepsy Center NHO Shizuoka Institute of Epilepsy and Neurological Disorders, Shizuoka, Japan

πŸ‡―πŸ‡΅

Yokohama City University Hospital, Yokohama-shi, Kanagawa, Japan

and more 8 locations

A Clinical Pharmacology Study of MT-3921 in Healthy Adult Males

Phase 1
Completed
Conditions
Healthy Adult Males
Interventions
Biological: MT-3921
Biological: Placebo
First Posted Date
2022-05-31
Last Posted Date
2023-01-18
Lead Sponsor
Mitsubishi Tanabe Pharma Corporation
Target Recruit Count
10
Registration Number
NCT05396235
Locations
πŸ‡―πŸ‡΅

Clinical Research Hospital Tokyo, Shinjuku-ku, Tokyo, Japan

Clinical Pharmacology Study of Oral Edaravone in Healthy Adult Subjects (Food Effect Study)

Phase 1
Completed
Conditions
Healthy Adult Subjects
Interventions
Drug: MT-1186
First Posted Date
2022-04-22
Last Posted Date
2024-01-05
Lead Sponsor
Mitsubishi Tanabe Pharma Corporation
Target Recruit Count
16
Registration Number
NCT05342597
Locations
πŸ‡―πŸ‡΅

Investigational site, Tokyo, Japan

A Clinical Pharmacological Study of MT-3921 in Subjects With HTLV-1 Associated Myelopathy (HAM)

Phase 1
Completed
Conditions
HTLV-1-Associated Myelopathy (HAM)
Interventions
Biological: MT-3921
Biological: Placebo
First Posted Date
2022-02-15
Last Posted Date
2024-01-29
Lead Sponsor
Mitsubishi Tanabe Pharma Corporation
Target Recruit Count
15
Registration Number
NCT05240612
Locations
πŸ‡―πŸ‡΅

St. Marianna University Hospital, Kawasaki-shi, Kanagawa, Japan

A Study of MT-0551 in Patients With Systemic Sclerosis

Phase 3
Recruiting
Conditions
Systemic Sclerosis
Interventions
Drug: Inebilizumab
Drug: Placebo
First Posted Date
2022-01-20
Last Posted Date
2024-07-05
Lead Sponsor
Mitsubishi Tanabe Pharma Corporation
Target Recruit Count
80
Registration Number
NCT05198557
Locations
πŸ‡―πŸ‡΅

University of Fukui Hospital, Yoshida-gun, Fukui, Japan

πŸ‡―πŸ‡΅

Kanazawa University Hospital, Kanazawa, Ishikawa, Japan

πŸ‡―πŸ‡΅

St. Marianna University Hospital, Kawasaki-shi, Kanagawa, Japan

and more 1 locations

Exploratory Study of MT-8554 in Subjects With Painful Diabetic Peripheral Neuropathy

Phase 2
Completed
Conditions
Painful Diabetic Peripheral Neuropathy
Interventions
Drug: MT-8554
Drug: Placebo
First Posted Date
2021-11-17
Last Posted Date
2022-11-22
Lead Sponsor
Mitsubishi Tanabe Pharma Corporation
Target Recruit Count
156
Registration Number
NCT05123196
Locations
πŸ‡―πŸ‡΅

Yachiyo Hospital, Anjo-City, Aichi, Japan

πŸ‡―πŸ‡΅

JUNEIKAI Medical Corporation Akaicho Clinic, Chiba-shi, Chiba, Japan

πŸ‡―πŸ‡΅

Medical Corporation Kouhoukai Takagi Hospital, Okawa-shi, Fukuoka, Japan

and more 30 locations

Comparative Bioavailability Study of Oral Edaravone Administered Orally and Via a Nasogastric Tube

Phase 1
Completed
Conditions
Healthy Adult Subjects
Interventions
Drug: MT-1186
First Posted Date
2021-03-01
Last Posted Date
2024-01-08
Lead Sponsor
Mitsubishi Tanabe Pharma Corporation
Target Recruit Count
36
Registration Number
NCT04776135
Locations
πŸ‡―πŸ‡΅

Investigational site, Tokyo, Toshima-ku, Japan

Β© Copyright 2025. All Rights Reserved by MedPath